Table 1. Baseline characteristics of the study cohort of 1147 patients with IgA nephropathy (IgAN).
| Total number | 1147 |
|---|---|
| Age (years) | 36±16 |
| Pediatric subjects (% <18 years old) | 15 |
| Male (%) | 73 |
| Ethnicity (% Caucasian/African/Asian/other) | 97.5/0.5/0.5/1.5 |
| eGFR (ml/min per 1.73m2) | 73±30 |
| CKD stage 1 or 2*, 3, 4, 5 (%) | 60, 28, 7, 2 |
| MAP (mm Hg) | 98±13 |
| SBP (mm Hg) | 131±23 |
| DBP (mm Hg) | 81±12 |
| Hypertensive subjects (%) | 65 |
| Proteinuria (g/day) | 1.3 (0.6–2.6) |
| Proteinuria g/day (%)<0.5, ⩾0.5 <1, ⩾1 <3, ⩾3 | 20, 20, 39, 21 |
| Before biopsy immunosuppressive treatments | 10 |
| Before biopsy nonimmunosuppressive treatments | |
| Prior tonsillectomy (%) | 4 |
| Prior RASB (%) | 39 |
Abbreviations: CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; MAP, mean arterial blood pressure; SBP, systolic blood pressure.
Results are expressed as mean±s.d., median (interquartile range), or percent. Hypertensive patients and proteinuria units: see Materials and Methods and definitions. RASB: renin–angiotensin system blockade by angiotensin-converting enzyme inhibitors and/or angiotensin receptors blockers.
CKD stages 1 and 2 were grouped in one only category owing to inaccuracy of MDRD measure of eGFR in stages 1 and 2.